Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a
study released today by the Healthcare business of Thomson Reuters.
During the study period, the average length of time sleep aids were used
by adults under age 45 increased more than 40 percent — rising from 64 days
in 1998 to 93 days in 2006.
“Insomnia, a condition traditionally associated with older adults, appears
to be causing larger numbers of young adults to turn to prescription sleep
aids, and to depend on them for longer periods of time,” said
PhD, senior vice president and general manager for the Healthcare business of
The study is based on medical and drug claims data from the Thomson
Reuters MarketScan(R) Research Databases. Results were weighted to reflect the
U.S. population with employer-sponsored health insurance.
Researchers found a 50-percent increase in the use of prescription sleep
aids among all adults under age 45 from 1998 to 2006. The most dramatic
increase was seen in the youngest segment of the study population, those
between the ages of 18 and 24, whose prevalence of use increased from 599
users per 100,000 in 1998 to 1,524 users per 100,000 in 2006. For those 25 to
34 years of age, use almost doubled from 1,372 users to 2,528 users per
Non-benzodiazepine hypnotics — such as Ambien CR and Lunesta — accounted
for almost two-thirds of all the prescription sleep aids used by this
A number of psychiatric, cognitive and conditioning factors are known to
perpetuate insomnia, and the study found that 25 percent of first-time sleep
aid users had a mental heath diagnosis in the month prior to sleep aid use.
However, fewer than 10 percent of these new users visited a mental health
professional prior to initiating sleep aid use. Most prescriptions were
provided by family-practice physicians, acute care hospitals and doctors
specializing in internal medicine and obstetrics/gynecology.
About Thomson Reuters
The Healthcare business of Thomson Reuters produces insights, information,
benchmarks and analysis that enable organizations to manage costs, improve
performance and enhance the quality of healthcare. Thomson Reuters is the
world’s leading source of intelligent information for businesses and
professionals. We combine industry expertise with innovative technology to
deliver critical information to leading decision makers in the financial,
legal, tax and accounting, scientific, healthcare and media markets, powered
by the world’s most trusted news organization. With headquarters in
and major operations in
more than 50,000 people in 93 countries. Thomson Reuters shares are listed on
the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI);
London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more
information, go to www.thomsonreuters.com.
SOURCE Thomson Reuters